Egils K. Bogdanovics, MD, and the expert panel review the TN10 study data on the efficacy of teplizumab in delaying the progression of T1D, which led to the drug’s approval from the FDA.
An analysis of real-world data provides an overview of the effects of GLP-1 receptor agonist and SGLT2 inhibitor use among adults with type 1 diabetes.